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Abstract: Titanium is used in a wide variety of materials ranging from medical devices to materials
used in everyday life. Adverse biological reactions that could occur in patients, consumers, and
workers should be monitored and prevented. There is a lack of available agents to test and predict
titanium-related hypersensitivity. The aim of this study was to develop two bioavailable titanium
substances in ionic and nanoparticulate form to serve as antigens for hypersensitivity testing in vitro.
Peripheral blood mononuclear cells from 20 test subjects were stimulated with the antigens and
secretion of monocytic and lymphatic cytokines and chemokines were measured by a multiplex bead
assay. Lymphocyte stimulation indices were also determined in a subset of test subjects by measuring
CD69 and HLA-DR expression by flow cytometry. Cytokine profiling revealed that both antigens
increased production of typical monocyte and macrophage secreted cytokines after 24 h, with significant
increases in IL-1β, IL-7, IL-10, IL-12, IL-2R, IL-6, GM-CSF, TNF-α, IL-1RA, MIP-1α, MIP-1β, IFN-α, and
IL-15. Lymphatic cytokines and chemokines were not significantly induced by activation. After seven
days of stimulation, ionic-Ti (2.5 µg/mL) caused proliferation (stimulation index > 2) of CD4+ cells and
CD8+ cells in all persons tested (N = 6), while titanium dioxide nanoparticles (50 µg/mL) only caused
significant proliferation of CD4+ cells. Our preliminary results show that the experimental titanium
antigens, especially the ionic form, induce a general inflammatory response in vitro. A relevant cohort of
test subjects is required to further elucidate their potential for predictive hypersensitivity testing.
Keywords: allergy; hypersensitivity; titanium; cytokine; lymphoproliferation; flow cytometry;
implant; multiplex bead assay; adverse effects of nanomaterials on immune system
1. Introduction
Titanium and its oxides are utilized broadly for the creation of materials, and it is estimated that
1.45 million metric tons were produced in the United States in 2007 [1]. The unique material properties
of titanium dioxide (TiO2), such as its high strength and ease of machinability, explain its extensive
use for creation of materials including paint, cosmetics, sunscreen, toothpaste, plastics, paper, textiles,
food packaging, and medical devices [2,3]. Therefore, exposure to titanium nanoparticles and titanium
materials is broad and affects consumers, patients, and people with occupational exposure [4–6].
Titanium materials were historically considered bio-inert, since metallic titanium is highly resistant
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to corrosion. However, in the last two decades the risks associated with titanium exposure have
been questioned in response to accumulating evidence of occupational and medicinal risks. In 2006,
the International Agency for Research on Cancer classified TiO2 as possibly carcinogenic to humans [7].
With the rapid development of nanotechnology, engineered TiO2 nanoparticles (NPs) have
become increasingly common, presenting additional exposure risks. NPs are defined as having
particle diameters less than 100 nm. Due to their small diameters, NPs are respirable and have a
large surface area to mass ratio, imparting an increased chemical reactivity. The National Institute
for Occupational Safety and Health has concluded that surface area is a critical metric for assessing
occupational respiratory exposure to TiO2, although the extent that these properties specifically
contribute to exposure risks has been debated [1,8]. Alternate NP exposure routes include topical
(skin), gastro-intestinal, and through wear and biocorrosion of medical implants. Once inside the
body, opsonization of metallic particles initiates monocyte/macrophage activation and subsequent
release of pro-inflammatory cytokines to recruit additional immune cells and promote immunological
activity, such as phagocytosis [9–11]. Both lymphocyte accumulation and macrophage infiltration
have been reported in the vicinity of titanium implants [12,13]. Inhalation is the most common
occupational exposure to TiO2, and assessment of bronchoalveolar lavage (BAL) fluid after intratracheal
administration of TiO2 nanoparticles in vivo induce recruitment of inflammatory cells, including
neutrophils, which are also known to phagocytose foreign pathogens and secrete granular contents
that can induce off target tissue damage [14]. Pulmonary inflammation, fibrosis, epithelial hyperplasia,
and tumorigenesis have all been reported in relation to dose and duration dependent models of in vivo
TiO2 exposure [8]. Thus, NPs may be significant contributors to immune responses, and interactions
between NPs and immune cells represent an emerging category of safety concern [15,16].
In addition to TiO2 NPs, titanium ions are also known to cause immune responses because of
their ability to bind to proteins, such as albumin or transferrin [17–19], creating an immunogenic
adduct capable of stimulating the immune system [20,21]. It is likely that ionic titanium released
from implants is stabilized by biomolecules such as citrate, which is one of the most important
low-molecular-mass metal chelators in cellular fluids, having a concentration of approximately 0.1 mM
in human plasma [22]. The coordination complexes of Ti(IV) citrate are relatively stable to hydrolysis
in aqueous solutions near neutral pH. However, it has been shown that proteins like transferrin and
albumin can exchange with the citrate ligand to create a bioavailable metalloprotein [23] that could
serve as an antigen in immunological reactions. Current methods for testing immune sensitivity and
the specific mechanisms of immune response to titanium NPs and ions are limited, partly due to the
lack of in vitro methods for synthesizing and evaluating human immunity. The current method for
predicting metal allergy is epicutaneous patch testing, although these tests can give false positive or
false negative results. Further, patch testing is rarely predictive of immunity from internal exposure due
to the low solubility of titanium salts and metals, thus reducing the ability of the metal to penetrate the
skin [11,24–26]. It has been shown that stable complexes of TiO2-nanoparticles bound to proteins can
be produced in vitro under physiological conditions, and these are candidates for use as antigens for
in vitro assessment of human immunity [27,28]. Additionally, in vitro reactivity to more bioavailable
titanium antigens may provide an alternative method for detecting unwanted immune responses or
serve as a novel method to study immunogenic cascades induced by TiO2 exposure.
Flow cytometry is a proven method for determining the lymphocyte stimulation index as a
measure of hypersensitivity to metals [29]. Additionally, the CD69 (cluster of differentiation 69)
surface antigen is one of the earliest markers of hypersensitivity and can be detected as early as
24 h after stimulation, [30,31] and class II tissue type antigens like HLA-DR (human leukocyte
antigen—antigen D related) are often expressed on activated antigen presenting cells, including
macrophage infiltrating cells [10]. Thus, lymphocyte stimulation indices and expression levels of
CD69 and HLA-DR serve as metrics for quantitative analysis of cellular hypersensitivity. Cytokine
expression levels can also be used as biomarkers of immunomodulatory properties. Many studies
have shown that proinflammatory cytokines such as IL-1β (interleukin 1beta), TNF-α (tumor necrosis
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factor-alpha), and GM-CSF (granulocyte-macrophage colony-stimulating factor) are co-upregulated
after hapten or particle stimulation [32–36]. Other cytokines—including IL-6 (interleukin 6), IFN-γ
(interferon gamma), IL-12 (interleukin 12), and IL-15 (interleukin 15)—are also linked with contact
sensitivity or particle stimulation [37–39]. These studies have been helpful in determining responses
from general metal sensitivity, but there is limited literature that specifically addresses human response
to titanium [40,41]. Most studies that include titanium focus on particulate titanium and exclude
ionic titanium completely. Due to the lack of consensus on cytokine responses to metals and the
limited knowledge available about hypersensitivity to titanium, a high throughput method would
be advantageous to measure a wide range of monocytic and lymphatic cytokines and chemokines in
response to novel titanium antigens in vitro.
In this study, we aimed to develop two bioavailable titanium substances in ionic and
nanoparticulate forms and test their potential as antigens for hypersensitivity testing in vitro. In a
small pilot, we tested the responses induced by these novel titanium antigens in 20 test subjects
by measuring lymphocyte stimulation indices, CD69 and HLA-DR expression, and a wide range
(multiplex) of both monocytic and lymphatic cytokines and chemokines in vitro.
2. Results
2.1. Endotoxin Levels
All test substances were tested for endotoxin levels and were found to be acceptable and below
1 EU/mL. Human serum albumin (HSA) was found to be the reagent that contributed to the endotoxin
level in the Ti-antigens, but HSA alone (negative control in N = 3 experiments) did not stimulate
cytokine release.
2.2. Lymphocyte Proliferation Responses to Titanium Antigens
PBMCs from all test subjects showed proliferative responses to positive controls PMA/I
(phorbol-myristate-acetate and ionomycin), PHA (phytohemagglutinin), and PPD (purified protein
derivative) (stimulation index (SI) >2) after seven days of stimulation. After seven days of stimulation
with the low concentration of ionic-Ti, two test subjects (2/6) showed significant proliferation of
CD4+ cells (Figure 1a). There were no subjects with significant proliferation of CD8+ cells after
stimulation with the low concentration of ionic-Ti. The high concentration of ionic-Ti caused significant
proliferation in all test subjects for both CD4+ cells (Figure 1a) and CD8+ cells after seven days of
stimulation (Figure 1b). Stimulation with the low concentration of nano-TiO2 for seven days caused
significant proliferation of CD4+ cells in two test subjects (2/6) (Figure 1c) but no test subjects had
significant proliferation of CD8+ cells. Stimulation with the high concentration of nano-TiO2 for seven
days caused significant CD4+ proliferation for all but one patient (5/6) (Figure 1c), and only induced
significant CD8+ proliferation for two test subjects (2/6).
Figure 1. Lymphocyte proliferation (stimulation index (SI) = % of stimulated CFSE positive cells
relative to the mean % of unstimulated control cells) of CD4+ cells and CD8+ cells after stimulation
with ionic-Ti (a (CD4+), b (CD8+)) and nano-TiO2 (c (CD4+)). (N = 6).
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2.3. Activation Marker Expression
After 48 h of activation, the lowest concentrations of ionic titanium antigens failed to induce
CD69 expression on either CD4+ cells or CD8+ cells (Figure 2a,b). With higher concentrations of ionic
titanium antigens, CD69 expression was increased in both cell types, however the increase was only
statistically significant in CD8+ cells (Figure 2b). HLA-DR expression was significantly increased after
stimulation with ionic-Ti. After seven days of stimulation with the high concentration of ionic-Ti,
CD4+ (Figure 2c) and CD8+ cells (Figure 2d) had an increase in HLA-DR expression when compared
to controls. There was no significant difference in CD69 expression or HLA-DR expression for CD4+
or CD8+ cells after stimulation with nano-TiO2 for seven days.
Figure 2. Expression of CD69 after 48 h (a,b) and HLA-DR after seven days (c,d) on CD4+ cells (a,c) and
CD8+ cells (b,d) after stimulation with ionic-Ti (N = 6). * Wilcoxon matched pair, p < 0.05.
2.4. Cytokine Release in Response to Titanium Antigens
PBMCs from all test subjects had increased expression of most cytokines in response to positive
controls PMA/I (except for Eotaxin, MCP-1 (Monocyte Chemoattractant Protein-1), IP-10 (Interferon
Gamma-Induced Protein-10), IL-8, IFN-γ and IL-6) and PHA (except for Eotaxin, IL-17, MCP-1, IFN-γ)
compared to unstimulated cells.
All test subjects had increased cytokine expression for a variety of cytokines after in vitro exposure
to nano-TiO2 and ionic-Ti for 24 h. A summary of all cytokine responses versus unstimulated controls
is shown in Figure 3. Out of the 24 cytokines measured, 16 cytokines were significantly increased after
stimulation with the nano-TiO2 and ionic-Ti: IL-1β (Figure 4a,b), IL-7, IL-10, IL-12, IL-2R (interleukin-2
receptor), IL-6 (Figure 4c,d), GM-CSF (Figure 4e,f), TNF-α, IL-1RA, MIP-1α (macrophage inflammatory
protein), MIP-1β, IL-15, IFN-γ, MCP-1, IL-8 and MIG (monokine induced by gamma interferon)
(only ionic-Ti).
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Figure 3. Statistical significance and median concentration (pg/mL) levels for cytokines and chemokines after PBMC stimulation in 24 h with low and high
concentrations of nano-TiO2, ionic-Ti and positive controls (PHA and PMA) versus unstimulated cells. * p < 0.05, ** p < 0.001 compared to control using Wilcoxon
signed rank test. Abbreviations: interleukin (IL), receptor (R), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF), interferon
(IFN), macrophage inflammatory protein (MIP), monocyte chemoattractant protein (MCP), interferon gamma induced protein-10 (IP-10), monocyte induced by
gamma interferon (MIG).
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Figure 4. Expression levels of IL-1β (a,b), IL-6 (c,d), and GM-CSF (e,f) were increased after stimulation
with either nano-Ti or ionic-Ti for 24 h. Graphs show median and interquartile range (N = 20).
*** p < 0.0001, ** p < 0.01, * p < 0.05.
3. Discussion
Exposure to both nanoparticulate TiO2 and ionic titanium poses risks, and a better understanding
of the adverse biological reactions from these materials will enhance both monitoring and prevention
of related health risks associated with the exposure. The exposure can be endogenous from surgically
implanted devices, such as hip and knee prostheses, or exogenous, such as through skin contact
or inhalation. Previous studies have shown elevated lymphocyte stimulation indices in patients
with problematic titanium implants, and occupational pulmonary exposure to TiO2 via inhalation
is commonly associated with adverse pulmonary outcomes including fibrosis and cancer. Inspired
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by these findings, we sought to investigate whether or not our newly developed Ti-antigens with
improved bioavailability and stability could be used in modern in vitro assays to reveal information
about the immunological potential of titanium substances [11].
3.1. Antigens
Titanium has historically been considered bio-inert in both its pure form and as an alloy due
to the passivating titanium dioxide layer that spontaneously forms after exposure to oxygen. While
this remains true for bulk titanium materials, TiO2 NPs and ions are no longer considered bio-inert
and ultrafine TiO2 is classified as a potential occupational carcinogen by the National Institute for
Occupational Safety and Health [1]. Medical implants are a source of endogenous exposure to
TiO2 NPs and ions, as both mechanical wear and prolonged inflammation can lead to material
corrosion [12,42–44]. Degradation products from implant corrosion include nano- and macroparticles,
free ions, and organometallic compounds [45–47]. Inhalation of engineered NPs is one of the most
common forms of exogenous occupational exposure to ultrafine TiO2 [8,48]. While immune cells,
including macrophages, clear TiO2 from the alveolar spaces via phagocytosis, overloading caused by
excessive particle inhalation limits macrophages’ ability to clear TiO2, causing prolonged exposure on
the order of years rather than days or months [49].
Previous studies have shown immune responses to titanium-based particles, but few studies have
been able to demonstrate immune responses to ionic titanium antigens [37,50–52]. This is partially
because of the lack of a stable ionic titanium antigen at sufficient concentrations for immunological
testing [21,53]. In this study, we were able to stabilize the Ti(IV)-ions in a physiological medium by
complexing it to HSA in a 2:1 molar ratio. To our knowledge, this is the first ionic titanium antigen
that has successfully induced an immune response in vitro. We propose that the Ti-albumin antigens
act as haptens typical for a type IV hypersensitivity reaction, but this must be further investigated in a
mechanistic study.
3.2. Flow Cytometry
Flow cytometry was used to measure lymphocyte proliferation via reduction of cytoplasmic CFSE
concentration (and thereby fluorescence intensity) upon cell division. Most report good correlation of
the CFSE-based test with the traditional tritiated thymidine incorporation when analyzing reactivity
to common antigens of protein nature [54], and this technique offers additional advantages due to
the avoidance of radioactive reagents and the enumeration of proliferative responses from specific
lymphocyte subpopulations. The usefulness of CFSE measurements in assessing beryllium sensitivity
has been investigated [55,56]. Additionally, immunophenotyping has previously been used to assess
immune cell activation in response to metal stimuli, demonstrating that chromium and nickel induce
expression of CD25 in CD4+ T cells [57]. Few studies have investigated immunophenotypic changes
in response to ionic and NP TiO2, though there is evidence that tetravalent ionic titanium induces
minor changes in CD25 and a major increase in CD69 expression, and that titanium ions decrease the
activation markers CD25 and HLA-DR on dendritic cells [58–60]. To our knowledge, combined CFSE
proliferation testing and immunophenotyping to analyze metal hypersensitivity has not previously
been done. Here we demonstrate that this multiparametric flow cytometry method may be well
suited to assess metal sensitivity in patients or employees with exposure to endogenous or exogenous
TiO2, respectively. Specifically, we identify HLA-DR as a measure of activation after seven days of
stimulation and use the CFSE stain to verify proliferative properties of activated cells.
3.3. Cytokines
The cytokines that were secreted in response to titanium in this study are primarily produced by
monocytes or macrophages, such as IL-10, IL-15, MIP-1β, IFN-γ, and IL-1RA. This is in accordance
with publications identifying macrophages as key regulators of both endogenous and exogenous TiO2
exposure. According to Gallo et al., the most important cells involved in the inflammatory response
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to prosthetic particles are the monocyte/macrophage lineage [61]. In addition, histological analysis
demonstrates that macrophages aggregate in the lung and contain TiO2 after either intratracheal
installation or inhalation of nanoscale TiO2 in vivo [62,63]. This work further strengthens the argument
that both titanium nanoparticles and ionic titanium antigens stimulate an immune response via
activation of macrophages/monocytes in patient PBMC cultures. In contrast, there was little or no
increase in lymphokine secretion after titanium stimulation, i.e., IL-2, IL-4, IL-5, IL-13, and IL-17
(Figure 3). This agrees with previous studies where neither lymphocyte stimulation nor increased
production of lymphokines IL-2 or IL-4 were seen after stimulation with titanium debris from metal
implants [52] or by subchronic intravenous exposure to palladium NPs [64].
Other types of metal particles, such as Co-Cr-Mo alloy particles, have been shown to stimulate
the inflammasome pathway via secretion of IL-1β and other monocytic cytokines, which suggests
that titanium debris could stimulate the same inflammatory pathway [34]. We saw a large increase
in IL-1β secretion after stimulation with Ti(IV)-albumin and nano-TiO2 (Figure 4a,b). This agrees
with previously observed increases in IL-1β after topical hapten application to murine ears or particle
stimulation in vitro [35,36,40]. Increased IL-1β secretion has also been seen specifically in response
to titanium wear debris from implants and in response to intratracheal installation, inhalation, or
intraperitoneal injection of nano-TiO2 [8,33,52,65–68].
Several studies have found that simultaneous increases in TNF-α, GM-CSF, and IL-6 accompany
secretion of IL-1β, which we also observed [33,35–37,69]. Specifically, TNF-α has been shown to
increase 40-fold after macrophage exposure to submicron sized titanium alloy particles for 48 h [37].
The release of these cytokines into sites of metal accumulation in vivo can subsequently contribute
to an immune response by recruiting and activating additional immune cells, prolonging immune
cell survival, and increasing production of reactive oxygen species (ROS) [70,71]. Our results support
previous work, as IL-1β, TNF-α, GM-CSF, and IL-6 were all increased in response to metal stimuli.
It has been proposed that IL-1/IL1RN/TNF-α genotyping and cytokine release assay scores may be
used as a new tool for individual risk assessment [72], and our data supports the hypothesis that
secretion levels may be a good measure of reactivity to nano-TiO2 exposure.
3.4. Possible Mechanism
Based on the work shown here, innate immunity is critical to initiate the immune response
to particulate TiO2, as we identify a strong upregulation in pro-inflammatory cytokines classically
associated with innate immunity, including TNF-α and IL-1β. As suggested by others, the data support
the hypothesis that macrophage activation is induced by TiO2 NPs and ions to increase secretion of
monocyte and macrophage derived cytokines and promote engulfment of the foreign materials [73].
The pro-inflammatory response observed here could also be in part due to toxic responses,
as toxicity studies of TiO2 nanoparticles demonstrate signs of apoptosis and necrosis at certain
concentrations [74]. Kongseng et al. provided evidence that PBMCs treated with TiO2-NPs at
concentrations ≥25 µg/mL for 24 h significantly reduced cell viability and significantly increased
production of toxic mediators such as ROS and inflammatory cytokines such as IL-6 and TNF-α [75].
However, the viability of the PBMCs in our study was not affected after 24 h and 7 days.
Lastly, it is possible that particulate TiO2 exposure induces an adaptive immune response via
antigen recognition by memory cells among PBMCs. There is evidence of T-lymphocyte mediated
immunity in response to chronic intravenous palladium administration in vivo, as key cytokines
involved in adaptive immunity were increased, including interferon gamma (IFNγ), IL-2, and
IL-4 [76]. This is in contrast to what was observed after subchronic palladium exposure, which
did not induce IFNγ, IL-2, or IL-4 [64]. Our work demonstrates that although lymphocyte proliferation
of CD4+ cells was observed at high concentrations of TiO2 exposure, IL-2 secretion was not increased.
This contradicts the hypothesis that lymphocytes become activated since T-lymphocyte proliferation
requires both IL-2 production and IL-2 receptor expression [52,77]. Taken together, these findings
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suggest that adaptive immunity is activated by particulate metal exposure; however, it is likely subject
to temporal regulation and requires chronic exposure, and may also be metal specific.
3.5. Limitations
The number of test subjects involved in this study was limited and with a mixed background and
thus we did not intend to compare subgroups. Another potential weakness might be the selection of
subjects who were referred for skin patch testing due to suspected metal allergy from occupational
causes. Six subjects tested positive on nickel. However, these subjects did not seem to respond more to
in vitro Ti-exposure, so we did not suspect any cross reactivity to nickel. The Ti substances were not
tested on the skin. Future experiments should aim to include two larger well-matched cohorts (with
respect to age, clinical history, gender, and exposure) in order to investigate significant differences
between relevant test groups.
In future studies, dose–response testing including at least a third stimulation concentration for
both may help to identify a toxic threshold. Also, chemical characterization of the antigens must
be carried out before use in larger cohort studies (ionic oxidation state, chemical structure, stability,
purity, etc.).
4. Materials and Methods
4.1. Test Subjects
Blood samples were obtained from twenty test subjects; 8 without implants and 12 with
titanium-based implants, primarily total joint replacements and metallic stents. The test subjects
without implants were recruited through the Department of Occupational Medicine due to suspected
contact allergy to nickel. Persons with implants attended regular controls at their respective clinics at
Haukeland University Hospital (Table 1).
Table 1. Test subject information, implant status, and general health
Patient Sex Age Metal Implants General Health
1 F 1965 - Healthy. Ni allergic
2 F 1968 - Healthy. Ni allergic
3 F 1993 - Healthy. Ni allergic
4 M 1968 - Healthy. Ni allergic
5 F 1964 - Healthy. Ni allergic
6 M 1964 - Healthy. Ni allergic and hand eczema.
7 M 1991 - Healthy. Hand eczema.
8 M 1973 - Healthy. Skin allergy. Hand eczema.
9 F 1963 THA 1 (1y) Diabetes, Joint/muscle disease
10 M 1968 THA Stroke (8 years ago)
11 M 1949 Plates/screws (22 y) Good
12 M 1943 Bilateral THA (1 y, 3 y) Good
13 F 1947 Bilateral THA (20 y) Osteoarthritis. Hip pain.
14 F 1974 Bilateral THA (11 y). Ti heart valve (15 y) Heart disease, Joint/Muscle disease or rheumatism
15 M 1934 Peripheral stent (2 y). Pacemaker (2 y) Diabetes, heart disease, Parkinson’s
16 M 1942 Two peripheral stents (12 y, 14 y) Parkinson’s and heart disease
17 F 1940 Aorta stent, re-stented twice due to restenosis Heart disease
18 M 1943 Stent graft (10 days) N/A 3
19 F N/A Nails/Screws right knee (11 y). TKA 2 left (6 y) High blood pressure, osteoarthritis, rhinitis and eczema
20 F 1984 Dental implants (6 y) Gastric/ Intestinal disease (IBS) and eczema
1 Total Hip Arthroplasty (THA), 2 Total Knee Arthroplasty (TKA). 3 No information (N/A).
4.2. Ethics
The study was conducted in accordance with the Declaration of Helsinki and was approved by
the Western Norway ethics committee (at the Haukeland University Hospital) in Bergen, Norway
(ethical permission no. 2013/66/REK Vest) and all test subjects gave informed consent.
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4.3. Blood Sample Collection and Processing
Blood samples were obtained by venipuncture in sterile BD vacutainer® ACD blood collection
tubes. Peripheral blood mononuclear cells (PBMCs) were isolated on the same day as collection
in LeucoSep® (Greiner Bio-One, Frickenhausen, Germany) density gradient centrifugation tubes
according to the established LeucoSep® method. The PBMC fraction was removed and washed
with EMEM medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 2.7% v/v sodium
bicarbonate, 1% v/v L-glutamine, and 1% v/v HEPES buffer (all from Lonza, BioWhittaker®, Basel,
Switzerland). PBMCs were suspended in RPMI-1640 medium (HEPES modification with 25 mM
HEPES and sodium bicarbonate, Sigma-Aldrich) supplemented with 1% v/v sodium pyruvate, 2.6%
v/v sodium bicarbonate, 1% v/v L-glutamine, penicillin streptomycin (97 U/mL pen, 97 U/mL strep),
amphotericin B (25 µg/mL) (all from Lonza, BioWhittaker®), 2% v/v D(+) glucose (Sigma-Aldrich,
St. Louis, MO, USA) containing either 20% heat-inactivated AB serum or 10% heat-inactivated fetal
bovine serum, for cytokine analysis or flow cytometry respectively. Cell concentrations and viability
were determined using trypan blue staining and Countess™ automated cell counter (Invitrogen,
LifeTechnologiesTM, Carlsbad, CA, USA).
4.4. Titanium Antigens Used for In Vitro Assays
Two forms of titanium antigens were developed, soluble ionic Ti(IV)-complexes and insoluble
TiO2-nanoparticles, both forms stabilized by albumin.
4.4.1. Ionic Titanium(IV) Albumin Antigens (Ionic-Ti)
Ti(III)citrate was made by mixing TiCl3 (0.134 M in HCl) with three-fold molar mass excess of
Na3citrate [23,78]. The pH was adjusted to pH 3 by NaOH. The solution was stirred for 24 h causing
oxidation of the Ti(III)citrate to Ti(IV)citrate [17]. The pH was adjusted to physiological pH 7.4 by
NaOH addition and diluted to a concentration of 33.5 mM Ti(IV)citrate.
Human serum albumin (HSA, Sigma-Aldrich, A3782-500MG) (0.2261 g) was dissolved in 3 mL
RPMI-1640 medium, followed by the addition of 200 µL Ti(IV)citrate (2:1 Ti:HSA molar ratio).
The solutions were allowed to mix overnight to facilitate citrate–albumin exchange. Ti(IV)albumin
was separated from residual Ti(IV)citrate in a 10 mL Zeba™ spin desalting column with a cut-off of
<1000 Da according to the manufacturer’s protocol. The column was washed with 2 mL RPMI-1640
and centrifuged for an additional 2 min (1000× g). The concentration of the final stock solution of
46.0 µg/mL was determined by inductively coupled plasma mass spectrometry (Element 2, Thermo
Finnigan, Bremen, Germany). The solution was stored at −20 ◦C and aliquots were thawed and
sterile filtered using the Whatman™ FP20/0.45 CA-S syringe filters. PBMCs were exposed to the ionic
Ti(IV)albumin antigen at 0.25 µg/mL and 2.5 µg/mL.
4.4.2. Nano-TiO2 Antigens
Commercially pure titanium dioxide (TiO2) nanoparticles, 99.9%, consisting of the crystallographic
forms anatase and rutile with an average diameter of <100 nm (MW05084, Sigma-Aldrich, St. Louis,
MO, USA) were used to make the stock suspension. Physicochemical characterization of the TiO2
nanoparticles and preparation of human serum albumin (HSA) stabilized nano-suspensions has
previously been shown [28,79]. A 1% TiO2 suspension was prepared by dissolving 0.2508 g TiO2 in
25 mL of milli-Q water. HSA (Sigma-Aldrich, A3782-500MG) (0.5002 g) was added to a glass bottle
and dissolved in RPMI-1640 medium. The HSA solution and the nano-TiO2 suspension were stored
at −20 ◦ C and 4 ◦C, respectively. Before each experiment a 0.1% nano-TiO2 suspension (sonicated
1 min at 70%, Sonics VibraCell™) was prepared by combining the HSA solution (500 µL) with the
nano-TiO2 suspension (100 µL, in RPMI-1640 medium 400 µL). The suspension was sterile filtered
immediately (Whatman™ FP20/0.45 CA-S syringe filters) and rotated at 10 rpm until used to minimize
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agglomeration of particles. The suspension was diluted and PBMCs were exposed to nano-TiO2 at
5 µg/mL and 50 µg/mL.
4.5. Endotoxin Testing
An endpoint chromogenic LAL test was performed on all test substances and three test subjects
samples using the Pierce® LAL Chromogenic Endotoxin Quantitation Kit (ThermoScientific, Pierce
Biotechnology, Rockford, IL, USA) according to the manufacturers’ protocol.
4.6. Flow Cytometry Analyses
PBMCs (10 × 106 cells/mL) were cultured in U-bottomed 96-well plates and exposed to metal
stimuli at the concentrations specified for each compound above. Phorbol myristate acetate (PMA,
Sigma-Aldrich, St. Louis, MO, USA), and Ionomycin (Calbiochem, Merck, Darmstad, Germany) at
10 ng/mL and 1 µg/mL, PHA at 2 µg/mL, and tuberculin purified protein derivative (PPD, Statens
Seruminstitutt, Copenhagen, Denmark) at 12.5 µg/mL were used as controls for cell viability and
media alone was used as a negative control. In order to enhance antigen stimulation, PBMCs were
co-stimulated with FastImmune™ CD28/49d (2 µL/well, except PHA and PMA/Ionomycin) (BD
Biosciences, San Jose, CA, USA). Experiments were run in duplicate. PBMC suspensions (total
volume 200 µL/well) were incubated at 37 ◦C and 5% CO2 in humidified air for 48 h and seven
days. For the seven day analysis, CFSE incorporation was used according to the manufacturer’s
protocol (Molecular Probes™, CellTrace™ CFSE Cell Proliferation Kit (C34554)) using 0.25 µL of 5 mM
stock CFSE solution per milliliter of cells giving a final working concentration of 1.25 µM. Cells with
no CFSE incorporation were used as a negative control. Gating on forward- and side-scatter plots
to exclude dead cells CD3+ cells in the lymphoid cluster were analyzed (Appendix A, Figure A1).
After 48 h of stimulation, activation-marker expression (CD69) on CD4+ and CD8+, gated from CD3+
T cells was measured using fluorochrome labeled antibodies to CD69 PE, CD4 Pacific Blue, CD3
APC-H7 (BD Biosciences, San Jose, CA, USA), CD8 FITC (Cytognos, Salamanca, Spain) and CD45
Pacific Orange (Invitrogen/Life Technologies, Waltham, MA, USA). After 7 days, cell proliferation
and HLA-DR positivity were measured on CD4+ and CD8+ after gating on CD3+ T cells using a
different panel of antibodies, in addition to CFSE (Invitrogen/Life Technologies, Waltham, MA, USA)
(Appendix A, Figure A2). Included in this panel were antibodies against CD3 Pacific Orange, CD4
APC, CD8 APC-H7 (BD Biosciences, Franklin Lakes, NJ, USA), HLA-DR Pacific Blue (Biolegend,
San Diego, CA, USA). All antibodies were titrated for optimal separation and staining intensities
of cell populations. Fifty microliters of an immediate premix of titrated antibodies was added to
fifty microliters of cells and incubated for 15 min at room temperature in the dark. The cells were
analyzed on a BD Canto II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA), fitted with three
lasers to obtain eight fluorochrome parameters in addition to scatter. The proliferation measured via
CFSE incorporation was normalized to the negative controls by calculating a stimulation index (SI) as
follows: SI = (percentage of stimulated cells CFSE positive)/(mean percentage of unstimulated control
cells CFSE positive). SI > 2 was considered significant. Blood samples from 6 of 20 test subjects were
included in flow cytometric analysis.
4.7. Cytokine Analyses
PBMCs (1.16 × 106 ± 6.4 × 105 cells/mL) were cultured in 24-well plates and exposed to metal
stimuli at the concentrations specified for each compound above. PMA/I (10 ng/mL, 1 µg/mL) and
PHA (2 µg/mL) were used as controls for cell viability and media alone was used as a negative control.
Experiments were run in duplicate. PBMC suspensions (total volume 500 µL/well) were incubated at
37 ◦C and 5% CO2 in humidified air for 24 h. Supernatants were isolated by centrifugation and stored
at −20 ◦C until further analysis and moved to −80 ◦C for long-term storage. The cytokine levels in
PBMC supernatants were obtained using a bead based multiplex cytokine detection kit (LHC0009,
Invitrogen/Life technologies, Camarillo, CA, USA) and the assay was carried out according to the
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manufacturer’s protocol. The multiplex kit measured the following 24 cytokines: IL-1β, IL-10, IFN-α,
IL-6, IL-12, Eotaxin, IL-13, IL-15, IL-17, MIP-1α, GM-CSF, MIP-1β, MCP-1, IL-5, IFN-γ, TNF-α, IL-1RA,
IL-2, IL-7, IP-10, IL-2R, MIG, IL-4, and IL-8 (abbreviations are defined in Table 1). The samples were
applied on a Luminex® 100™ instrument (Luminex Corporation, Austin, TX, USA), and data was
captured and analyzed by StarStation v.3 software (AppliedCytometry, Dinnington, Sheffield, UK).
RANTES was also measured, but data was excluded because most of the concentrations were outside
of the measurable range. For all other cytokines, infrequent values outside of the measurable range
were assumed to be 0. Blood samples from all twenty test subjects were included in cytokine analysis.
4.8. Statistical Analysis
The Wilcoxon matched-pair signed rank test was used to compare CD69 and HLA-DR expression
among all conditions (negative controls and low and high concentrations of each metal stimulus).
The Wilcoxon matched-pair signed rank test was also used to compare cytokine responses between
unstimulated cells with all other conditions (positive controls and Ti antigens). p-values < 0.05 were
considered to be statistically significant. All tests were performed using the GraphPad Prism statistics
software version 7.03.
5. Conclusions
We have shown that both nanoparticulate and ionic titanium antigens initiate immune responses
in vitro. In general, the higher concentrations of both forms of titanium elicit higher responses than
the lower concentrations, and the Ti(IV)-albumin elicits a greater immune response than nano-TiO2.
This trend was seen in stimulation indices, HLA-DR expression, and in cytokine secretion. Of the
24 cytokines measured, about half of them showed very significant differences after stimulation with
both forms of titanium. The majority of cytokines with increased expression were macrophage and
monocyte type cytokines, suggesting that immune activation is via this pathway. Our preliminary
results show that many of the responses to titanium antigens were general and were induced in all
test subjects. Further investigation is also necessary to elucidate the mechanism by which titanium
substances induces allergic responses in vivo, and to develop a diagnostic tool for both chronically
exposed workers and adverse reactions to implants.
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Appendix A
Figure A1. Flow charts showing gating of negative controls. (A) Gating on CD3+ lymphoid cells.
(B) CD4+ cells (green), CD8+ cells red). (C) Activated effector T helper cells (CD45RO+/HLA-DR+) in
upper right quadrant. (D) Activated effector T cytotoxic cells (CD45RO+/HLA-DR+). (E) CFSE-staining
of CD4+ T cells showing no cell division. (F) CFSE-staining of CD8+ T cells showing no cell division.
Int. J. Mol. Sci. 2018, 19, 1101 14 of 18
Figure A2. Flow chart example of the gating for the stimulated cell populations (2.5 ug/L ionic-Ti
after seven days). (A) Gating on CD3+ lymphoid cells. (B) CD4+ cells (green), CD8+ cells (red).
(C) Activated effector T helper cells (CD45RO+/HLA-DR+) in upper right quadrant. (D) Activated
effector T cytotoxic cells (CD45RO+/HLA-DR+) in upper right quadrant. (E) CFSE-staining of CD4+
T cells showing cell division in several generations. (F) CFSE-staining of CD8+ T cells showing cell
division in several generations.
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